All posts tagged "Neladalkib"

Royalty Pharma Acquires Up to $315 Million in Cancer Drug Royalties

Royalty Pharma has announced the acquisition of a pre-existing royalty interest in Nuvalent’s promising cancer drug candidates, neladalkib and zidesamtinib, for a total consideration of up...